| Drug General Information |
| Drug ID |
D0D8OY
|
| Former ID |
DNC009758
|
| Drug Name |
AP-24226
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H20F3N7O
|
| Canonical SMILES |
CC1=C(C=C(C=C1)C(=O)NC2=NC=CC(=C2)C(F)(F)F)C=CN3C=NC4=C<br />3N=CN=C4NC5CC5
|
| InChI |
1S/C24H20F3N7O/c1-14-2-3-16(23(35)33-19-11-17(6-8-28-19)24(25,26)27)10-15(14)7-9-34-13-31-20-21(32-18-4-5-18)29-12-30-22(20)34/h2-3,6-13,18H,4-5H2,1H3,(H,28,33,35)(H,29,30,32)/b9-7+
|
| InChIKey |
PPHMKXKASWTCSZ-VQHVLOKHSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Proto-oncogene tyrosine-protein kinase SRC |
Target Info |
Inhibitor |
[1]
|
|---|
| Proto-oncogene c-Abl |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
Chemokine signaling pathway
|
|
Endocytosis
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Tight junction
|
|
Gap junction
|
|
Platelet activation
|
|
GABAergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancerhsa04012:ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditis
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson disease
|
|
CCKR signaling map STP00008:Axon guidance mediated by Slit/Robo
|
|
Pathway Interaction Database
|
Endothelins
|
|
Signaling events mediated by PRL
|
|
LPA receptor mediated events
|
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
Plasma membrane estrogen receptor signaling
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Signaling events mediated by PTP1B
|
|
S1P3 pathway
|
|
EPHB forward signaling
|
|
Nectin adhesion pathway
|
|
Regulation of p38-alpha and p38-beta
|
|
CDC42 signaling events
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
Netrin-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
CXCR4-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Class I PI3K signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Regulation of Androgen receptor activity
|
|
E-cadherin signaling in the nascent adherens junction
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
EPHA forward signaling
|
|
E-cadherin signaling in keratinocytes
|
|
PDGFR-beta signaling pathway
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-2-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
Syndecan-3-mediated signaling events
|
|
Ephrin B reverse signaling
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
EPHA2 forward signaling
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Alpha4 beta1 integrin signaling events
|
|
Signaling events mediated by focal adhesion kinasep73pathway:p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Pregnane X Receptor pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL-3 Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Angiogenesis
|
|
Androgen receptor signaling pathwayWP2864:Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Pathogenic Escherichia coli infection
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet production
|
| References |
| REF 1 | J Med Chem. 2009 Aug 13;52(15):4743-56.9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. |
|---|
| REF 2 | J Med Chem. 2010 Jun 24;53(12):4701-19.Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent,orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. |
|---|
